Knight Therapeutics (TSE:GUD) Reaches New 1-Year High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as C$8.04 and last traded at C$7.86, with a volume of 37887 shares changing hands. The stock had previously closed at C$7.51.

Knight Therapeutics Stock Performance

The company has a debt-to-equity ratio of 10.15, a current ratio of 2.39 and a quick ratio of 1.79. The company has a market capitalization of C$815.83 million, a PE ratio of -166.40, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.21. The firm’s fifty day simple moving average is C$6.99 and its 200 day simple moving average is C$6.34.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%. The company had revenue of C$147.59 million for the quarter. On average, research analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.